TY  - JOUR
AU  - Ostojić, Marija
AU  - Jevrić, Marko
AU  - Mitrović-Ajtić, Olivera
AU  - Živić, Kristina
AU  - Tanić, Miljana
AU  - Čavić, Milena
AU  - Srdić-Rajić, Tatjana
AU  - Grahovac, Jelena
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1396
AB  - Due to the development of resistance to previously effective therapies, there is a constant need for novel treatment modalities for metastatic melanoma. Nischarin (NISCH) is a druggable scaffolding protein reported as a tumor suppressor and a positive prognostic marker in breast and ovarian cancers through regulation of cancer cell survival, motility and invasion. The aim of this study was to examine the expression and potential role of nischarin in melanoma. We found that nischarin expression was decreased in melanoma tissues compared to the uninvolved skin, and this was attributed to the presence of microdeletions and hyper-methylation of the NISCH promoter in the tumor tissue. In addition to the previously reported cytoplasmic and membranous localization, we observed nischarin in the nuclei in melanoma patients’ tissues. NISCH expression in primary melanoma had favorable prognostic value for female patients, but, unexpectedly, high NISCH expression predicted worse prognosis for males. Gene set enrichment analysis suggested significant sex-related disparities in predicted association of NISCH with several signaling pathways, as well as with different tumor immune infiltrate composition in male and female patients. Taken together, our results imply that nischarin may have a role in melanoma progression, but that fine-tuning of the pathways it regulates is sex-dependent.
T2  - Research Square
T1  - Nischarin expression may have differing roles in male and female melanoma patients
DO  - 10.21203/rs.3.rs-1576440/v2
ER  - 

@article{
author = "Ostojić, Marija and Jevrić, Marko and Mitrović-Ajtić, Olivera and Živić, Kristina and Tanić, Miljana and Čavić, Milena and Srdić-Rajić, Tatjana and Grahovac, Jelena",
year = "2023",
abstract = "Due to the development of resistance to previously effective therapies, there is a constant need for novel treatment modalities for metastatic melanoma. Nischarin (NISCH) is a druggable scaffolding protein reported as a tumor suppressor and a positive prognostic marker in breast and ovarian cancers through regulation of cancer cell survival, motility and invasion. The aim of this study was to examine the expression and potential role of nischarin in melanoma. We found that nischarin expression was decreased in melanoma tissues compared to the uninvolved skin, and this was attributed to the presence of microdeletions and hyper-methylation of the NISCH promoter in the tumor tissue. In addition to the previously reported cytoplasmic and membranous localization, we observed nischarin in the nuclei in melanoma patients’ tissues. NISCH expression in primary melanoma had favorable prognostic value for female patients, but, unexpectedly, high NISCH expression predicted worse prognosis for males. Gene set enrichment analysis suggested significant sex-related disparities in predicted association of NISCH with several signaling pathways, as well as with different tumor immune infiltrate composition in male and female patients. Taken together, our results imply that nischarin may have a role in melanoma progression, but that fine-tuning of the pathways it regulates is sex-dependent.",
journal = "Research Square",
title = "Nischarin expression may have differing roles in male and female melanoma patients",
doi = "10.21203/rs.3.rs-1576440/v2"
}

Ostojić, M., Jevrić, M., Mitrović-Ajtić, O., Živić, K., Tanić, M., Čavić, M., Srdić-Rajić, T.,& Grahovac, J.. (2023). Nischarin expression may have differing roles in male and female melanoma patients. in Research Square.
https://doi.org/10.21203/rs.3.rs-1576440/v2

Ostojić M, Jevrić M, Mitrović-Ajtić O, Živić K, Tanić M, Čavić M, Srdić-Rajić T, Grahovac J. Nischarin expression may have differing roles in male and female melanoma patients. in Research Square. 2023;.
doi:10.21203/rs.3.rs-1576440/v2 .

Ostojić, Marija, Jevrić, Marko, Mitrović-Ajtić, Olivera, Živić, Kristina, Tanić, Miljana, Čavić, Milena, Srdić-Rajić, Tatjana, Grahovac, Jelena, "Nischarin expression may have differing roles in male and female melanoma patients" in Research Square (2023),
https://doi.org/10.21203/rs.3.rs-1576440/v2 . .

TY  - JOUR
AU  - Ružić, Dušan
AU  - Đoković, Nemanja
AU  - Srdić-Rajić, Tatjana
AU  - Echeverria, Cesar
AU  - Nikolić, Katarina
AU  - Santibanez, Juan F.
PY  - 2022
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1212
AB  - The dysregulation of gene expression is a critical event involved in all steps of tumorigenesis. Aberrant histone and non-histone acetylation modifications of gene expression due to the abnormal activation of histone deacetylases (HDAC) have been reported in hematologic and solid types of cancer. In this sense, the cancer-associated epigenetic alterations are promising targets for anticancer therapy and chemoprevention. HDAC inhibitors (HDACi) induce histone hyperacetylation within target proteins, altering cell cycle and proliferation, cell differentiation, and the regulation of cell death programs. Over the last three decades, an increasing number of synthetic and naturally derived compounds, such as dietary-derived products, have been demonstrated to act as HDACi and have provided biological and molecular insights with regard to the role of HDAC in cancer. The first part of this review is focused on the biological roles of the Zinc-dependent HDAC family in malignant diseases. Accordingly, the small-molecules and natural products such as HDACi are described in terms of cancer therapy and chemoprevention. Furthermore, structural considerations are included to improve the HDACi selectivity and combinatory potential with other specific targeting agents in bifunctional inhibitors and proteolysis targeting chimeras. Additionally, clinical trials that combine HDACi with current therapies are discussed, which may open new avenues in terms of the feasibility of HDACi’s future clinical applications in precision cancer therapies.
T2  - Pharmaceutics
T1  - Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
IS  - 1
SP  - 209
VL  - 14
DO  - 10.3390/pharmaceutics14010209
ER  - 

@article{
author = "Ružić, Dušan and Đoković, Nemanja and Srdić-Rajić, Tatjana and Echeverria, Cesar and Nikolić, Katarina and Santibanez, Juan F.",
year = "2022",
abstract = "The dysregulation of gene expression is a critical event involved in all steps of tumorigenesis. Aberrant histone and non-histone acetylation modifications of gene expression due to the abnormal activation of histone deacetylases (HDAC) have been reported in hematologic and solid types of cancer. In this sense, the cancer-associated epigenetic alterations are promising targets for anticancer therapy and chemoprevention. HDAC inhibitors (HDACi) induce histone hyperacetylation within target proteins, altering cell cycle and proliferation, cell differentiation, and the regulation of cell death programs. Over the last three decades, an increasing number of synthetic and naturally derived compounds, such as dietary-derived products, have been demonstrated to act as HDACi and have provided biological and molecular insights with regard to the role of HDAC in cancer. The first part of this review is focused on the biological roles of the Zinc-dependent HDAC family in malignant diseases. Accordingly, the small-molecules and natural products such as HDACi are described in terms of cancer therapy and chemoprevention. Furthermore, structural considerations are included to improve the HDACi selectivity and combinatory potential with other specific targeting agents in bifunctional inhibitors and proteolysis targeting chimeras. Additionally, clinical trials that combine HDACi with current therapies are discussed, which may open new avenues in terms of the feasibility of HDACi’s future clinical applications in precision cancer therapies.",
journal = "Pharmaceutics",
title = "Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention",
number = "1",
pages = "209",
volume = "14",
doi = "10.3390/pharmaceutics14010209"
}

Ružić, D., Đoković, N., Srdić-Rajić, T., Echeverria, C., Nikolić, K.,& Santibanez, J. F.. (2022). Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. in Pharmaceutics, 14(1), 209.
https://doi.org/10.3390/pharmaceutics14010209

Ružić D, Đoković N, Srdić-Rajić T, Echeverria C, Nikolić K, Santibanez JF. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. in Pharmaceutics. 2022;14(1):209.
doi:10.3390/pharmaceutics14010209 .

Ružić, Dušan, Đoković, Nemanja, Srdić-Rajić, Tatjana, Echeverria, Cesar, Nikolić, Katarina, Santibanez, Juan F., "Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention" in Pharmaceutics, 14, no. 1 (2022):209,
https://doi.org/10.3390/pharmaceutics14010209 . .

TY  - JOUR
AU  - Ružić, Dušan
AU  - Ellinger, Bernhard
AU  - Đoković, Nemanja
AU  - Santibanez, Juan F.
AU  - Gul, Sheraz
AU  - Beljkaš, Milan
AU  - Đurić, Ana
AU  - Ganesan, Arasu
AU  - Pavić, Aleksandar
AU  - Srdić-Rajić, Tatjana
AU  - Petković, Miloš
AU  - Nikolić, Katarina
PY  - 2022
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1271
AB  - Abstract  Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors. Despite this presumed benefit, considerably more non-selective HDAC inhibitors have undergone clinical trials. In this report, we detail the design and discovery of potent HDAC inhibitors, with 1-benzhydryl piperazine as a surface recognition group, that differ in hydrocarbon linker. In vitro HDAC screening identified two selective HDAC6 inhibitors with nanomolar IC50 values, as well as two non-selective nanomolar HDAC inhibitors. Structure-based molecular modeling was employed to study the influence of linker chemistry of synthesized inhibitors on HDAC6 potency. The breast cancer cell lines (MDA-MB-231 and MCF-7) were used to evaluate compound-mediated in vitro anti-cancer, anti-migratory, and anti-invasive activities. Experiments on the zebrafish MDA-MB-231 xenograft model revealed that a novel non-selective HDAC inhibitor with a seven-carbon-atom linker exhibits potent anti-tumor, anti-metastatic, and anti-angiogenic effects when tested at low micromolar concentrations.
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
T2  - Pharmaceutics
T1  - Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation
IS  - 12
SP  - 2600
VL  - 14
DO  - 10.3390/pharmaceutics14122600
ER  - 

@article{
author = "Ružić, Dušan and Ellinger, Bernhard and Đoković, Nemanja and Santibanez, Juan F. and Gul, Sheraz and Beljkaš, Milan and Đurić, Ana and Ganesan, Arasu and Pavić, Aleksandar and Srdić-Rajić, Tatjana and Petković, Miloš and Nikolić, Katarina",
year = "2022",
abstract = "Abstract  Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors. Despite this presumed benefit, considerably more non-selective HDAC inhibitors have undergone clinical trials. In this report, we detail the design and discovery of potent HDAC inhibitors, with 1-benzhydryl piperazine as a surface recognition group, that differ in hydrocarbon linker. In vitro HDAC screening identified two selective HDAC6 inhibitors with nanomolar IC50 values, as well as two non-selective nanomolar HDAC inhibitors. Structure-based molecular modeling was employed to study the influence of linker chemistry of synthesized inhibitors on HDAC6 potency. The breast cancer cell lines (MDA-MB-231 and MCF-7) were used to evaluate compound-mediated in vitro anti-cancer, anti-migratory, and anti-invasive activities. Experiments on the zebrafish MDA-MB-231 xenograft model revealed that a novel non-selective HDAC inhibitor with a seven-carbon-atom linker exhibits potent anti-tumor, anti-metastatic, and anti-angiogenic effects when tested at low micromolar concentrations.",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
journal = "Pharmaceutics",
title = "Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation",
number = "12",
pages = "2600",
volume = "14",
doi = "10.3390/pharmaceutics14122600"
}

Ružić, D., Ellinger, B., Đoković, N., Santibanez, J. F., Gul, S., Beljkaš, M., Đurić, A., Ganesan, A., Pavić, A., Srdić-Rajić, T., Petković, M.,& Nikolić, K.. (2022). Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation. in Pharmaceutics
Multidisciplinary Digital Publishing Institute (MDPI)., 14(12), 2600.
https://doi.org/10.3390/pharmaceutics14122600

Ružić D, Ellinger B, Đoković N, Santibanez JF, Gul S, Beljkaš M, Đurić A, Ganesan A, Pavić A, Srdić-Rajić T, Petković M, Nikolić K. Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation. in Pharmaceutics. 2022;14(12):2600.
doi:10.3390/pharmaceutics14122600 .

Ružić, Dušan, Ellinger, Bernhard, Đoković, Nemanja, Santibanez, Juan F., Gul, Sheraz, Beljkaš, Milan, Đurić, Ana, Ganesan, Arasu, Pavić, Aleksandar, Srdić-Rajić, Tatjana, Petković, Miloš, Nikolić, Katarina, "Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation" in Pharmaceutics, 14, no. 12 (2022):2600,
https://doi.org/10.3390/pharmaceutics14122600 . .

TY  - JOUR
AU  - Mojsilović, Sonja
AU  - Tošić, Milica
AU  - Mojsilović, Slavko
AU  - Živanović, Marija
AU  - Bjelica, Sunčica
AU  - Srdić-Rajić, Tatjana
AU  - Santibanez, Juan F.
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1067
AB  - Purpose: Transforming growth factor-beta (TGF-beta) induces alternative macrophage activation that favors tumor progression and immunosuppression. Meanwhile, paclitaxel (PTx) induces macrophage (M phi) polarization towards antitumor phenotype. TGF-beta also increases tumor stroma macrophage recruitment by mechanisms that include cell motility enhancement and extracellular matrix degradation. In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta. Methods: We used mouse macrophage RAW 264.7 cells treated with PTx and TGF-beta combinations. Proliferation was analyzed by MTT and cell cycle assays. Immunofluorescence was performed to determine tubulin cytoskeleton and Smad3 nuclear localization. Western blot and transcriptional luciferase reporters were used to measure signal transduction activation. Migration was determined by wound healing assay. uPA activity was determined by zymography assay. Results: PTx decreased RAW 264.7 cell proliferation by inducing G2/M cell cycle arrest and profoundly modified the tubulin cytoskeleton. Also, PTx inhibited TGF-beta-induced Smad3 activation. Furthermore, PTx decreased cell migration and uPA expression stimulated by TGF-beta. Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition. Conclusions: PTx inhibits TGF-beta induction of mouse M phi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance MT anticancer action within tumors.
PB  - Balkan Union of Oncology (B.U.ON.)
T2  - Journal of BUON
T1  - Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration
EP  - 1265
IS  - 2
SP  - 1257
VL  - 25
UR  - https://hdl.handle.net/21.15107/rcub_rimi_1067
ER  - 

@article{
author = "Mojsilović, Sonja and Tošić, Milica and Mojsilović, Slavko and Živanović, Marija and Bjelica, Sunčica and Srdić-Rajić, Tatjana and Santibanez, Juan F.",
year = "2020",
abstract = "Purpose: Transforming growth factor-beta (TGF-beta) induces alternative macrophage activation that favors tumor progression and immunosuppression. Meanwhile, paclitaxel (PTx) induces macrophage (M phi) polarization towards antitumor phenotype. TGF-beta also increases tumor stroma macrophage recruitment by mechanisms that include cell motility enhancement and extracellular matrix degradation. In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta. Methods: We used mouse macrophage RAW 264.7 cells treated with PTx and TGF-beta combinations. Proliferation was analyzed by MTT and cell cycle assays. Immunofluorescence was performed to determine tubulin cytoskeleton and Smad3 nuclear localization. Western blot and transcriptional luciferase reporters were used to measure signal transduction activation. Migration was determined by wound healing assay. uPA activity was determined by zymography assay. Results: PTx decreased RAW 264.7 cell proliferation by inducing G2/M cell cycle arrest and profoundly modified the tubulin cytoskeleton. Also, PTx inhibited TGF-beta-induced Smad3 activation. Furthermore, PTx decreased cell migration and uPA expression stimulated by TGF-beta. Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition. Conclusions: PTx inhibits TGF-beta induction of mouse M phi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance MT anticancer action within tumors.",
publisher = "Balkan Union of Oncology (B.U.ON.)",
journal = "Journal of BUON",
title = "Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration",
pages = "1265-1257",
number = "2",
volume = "25",
url = "https://hdl.handle.net/21.15107/rcub_rimi_1067"
}

Mojsilović, S., Tošić, M., Mojsilović, S., Živanović, M., Bjelica, S., Srdić-Rajić, T.,& Santibanez, J. F.. (2020). Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration. in Journal of BUON
Balkan Union of Oncology (B.U.ON.)., 25(2), 1257-1265.
https://hdl.handle.net/21.15107/rcub_rimi_1067

Mojsilović S, Tošić M, Mojsilović S, Živanović M, Bjelica S, Srdić-Rajić T, Santibanez JF. Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration. in Journal of BUON. 2020;25(2):1257-1265.
https://hdl.handle.net/21.15107/rcub_rimi_1067 .

Mojsilović, Sonja, Tošić, Milica, Mojsilović, Slavko, Živanović, Marija, Bjelica, Sunčica, Srdić-Rajić, Tatjana, Santibanez, Juan F., "Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration" in Journal of BUON, 25, no. 2 (2020):1257-1265,
https://hdl.handle.net/21.15107/rcub_rimi_1067 .

TY  - CONF
AU  - Vidosavljević, Marija
AU  - Srdić-Rajić, Tatjana
AU  - Mitrović-Ajtić, Olivera
AU  - Jevrić, Marko
AU  - Grahovac, Jelena
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1399
AB  - Melanoma is the deadliest form of skin cancer. Despite the advancements in targeted 
BRAF and MEK therapy and immunotherapies, metastatic melanoma patients still 
have poor prognosis with a median survival of 9 months and a long-term survival rate 
of 10%. There is an urgent need for novel treatment modalities that target metastatic 
melanoma. Imidazoline I1 receptor (IR1, IRAS, NISCH) is a scaffolding protein that 
has been shown to be a tumor suppressor in breast cancer through regulation of 
cancer cell survival, motility and invasion. IR1 role in metastatic melanoma has 
not been investigated to date. Of importance, several IR1 agonists are clinically 
approved for treatment of hypertension. The aim of this study was to examine the 
IR1 expression in melanoma and the effects of IR1 agonists on melanoma cell 
viability. To confirm the target expression, we first determined IR1 levels in primary 
and metastatic melanoma patient samples by qRT-PCR and immunohistochemistry. 
We found that it is expressed in primary tumors and liver metastases and, to a lesser 
extent, in metastatic lymph nodes. Next, we examined the activity of IR1 agonists 
– rilmenidine, clonidine and moxonidine – in a panel of metastatic melanoma cell 
lines (HTB140, FemX-1, A375 and 518a2) and found that rilmenidine most potently 
inhibited cell viability. Notably, it was not toxic towards human dermal fibroblasts 
and keratinocytes. Furthermore, rilmenidine time- and dose- dependently induced 
cell cycle arrest in G2/M phase and consequent apoptosis. Our results imply that 
imidazoline I1 receptor is potentially novel anti-melanoma target, and that its already 
clinically approved agents have promising anti-cancer activity.
PB  - European Association for Cancer Research
C3  - 5th EACR Conference A Matter of Life or Death Mechanisms, Models and Therapeutic Opportunities, 12-14 February 2020, Bergamo, Italy
T1  - Potential anti-melanoma activity of Imidazoline I1 receptor agonists
EP  - 92
SP  - 92
UR  - https://hdl.handle.net/21.15107/rcub_rimi_1399
ER  - 

@conference{
author = "Vidosavljević, Marija and Srdić-Rajić, Tatjana and Mitrović-Ajtić, Olivera and Jevrić, Marko and Grahovac, Jelena",
year = "2020",
abstract = "Melanoma is the deadliest form of skin cancer. Despite the advancements in targeted 
BRAF and MEK therapy and immunotherapies, metastatic melanoma patients still 
have poor prognosis with a median survival of 9 months and a long-term survival rate 
of 10%. There is an urgent need for novel treatment modalities that target metastatic 
melanoma. Imidazoline I1 receptor (IR1, IRAS, NISCH) is a scaffolding protein that 
has been shown to be a tumor suppressor in breast cancer through regulation of 
cancer cell survival, motility and invasion. IR1 role in metastatic melanoma has 
not been investigated to date. Of importance, several IR1 agonists are clinically 
approved for treatment of hypertension. The aim of this study was to examine the 
IR1 expression in melanoma and the effects of IR1 agonists on melanoma cell 
viability. To confirm the target expression, we first determined IR1 levels in primary 
and metastatic melanoma patient samples by qRT-PCR and immunohistochemistry. 
We found that it is expressed in primary tumors and liver metastases and, to a lesser 
extent, in metastatic lymph nodes. Next, we examined the activity of IR1 agonists 
– rilmenidine, clonidine and moxonidine – in a panel of metastatic melanoma cell 
lines (HTB140, FemX-1, A375 and 518a2) and found that rilmenidine most potently 
inhibited cell viability. Notably, it was not toxic towards human dermal fibroblasts 
and keratinocytes. Furthermore, rilmenidine time- and dose- dependently induced 
cell cycle arrest in G2/M phase and consequent apoptosis. Our results imply that 
imidazoline I1 receptor is potentially novel anti-melanoma target, and that its already 
clinically approved agents have promising anti-cancer activity.",
publisher = "European Association for Cancer Research",
journal = "5th EACR Conference A Matter of Life or Death Mechanisms, Models and Therapeutic Opportunities, 12-14 February 2020, Bergamo, Italy",
title = "Potential anti-melanoma activity of Imidazoline I1 receptor agonists",
pages = "92-92",
url = "https://hdl.handle.net/21.15107/rcub_rimi_1399"
}

Vidosavljević, M., Srdić-Rajić, T., Mitrović-Ajtić, O., Jevrić, M.,& Grahovac, J.. (2020). Potential anti-melanoma activity of Imidazoline I1 receptor agonists. in 5th EACR Conference A Matter of Life or Death Mechanisms, Models and Therapeutic Opportunities, 12-14 February 2020, Bergamo, Italy
European Association for Cancer Research., 92-92.
https://hdl.handle.net/21.15107/rcub_rimi_1399

Vidosavljević M, Srdić-Rajić T, Mitrović-Ajtić O, Jevrić M, Grahovac J. Potential anti-melanoma activity of Imidazoline I1 receptor agonists. in 5th EACR Conference A Matter of Life or Death Mechanisms, Models and Therapeutic Opportunities, 12-14 February 2020, Bergamo, Italy. 2020;:92-92.
https://hdl.handle.net/21.15107/rcub_rimi_1399 .

Vidosavljević, Marija, Srdić-Rajić, Tatjana, Mitrović-Ajtić, Olivera, Jevrić, Marko, Grahovac, Jelena, "Potential anti-melanoma activity of Imidazoline I1 receptor agonists" in 5th EACR Conference A Matter of Life or Death Mechanisms, Models and Therapeutic Opportunities, 12-14 February 2020, Bergamo, Italy (2020):92-92,
https://hdl.handle.net/21.15107/rcub_rimi_1399 .

TY  - JOUR
AU  - Grahovac, Jelena
AU  - Srdić-Rajić, Tatjana
AU  - Santibanez, Juan F.
AU  - Pavlović, Marijana
AU  - Cavić, Milena
AU  - Radulović, Siniša
PY  - 2019
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/975
AB  - Objective: Despite recent advancements in targeted therapy and immunotherapies, prognosis for metastatic melanoma patients remains extremely poor. Development of resistance to previously effective treatments presents a serious challenge and new approaches for melanoma treatment are urgently needed. The objective of this study was to examine the effects of telmisartan, an AGTR1 inhibitor and a partial agonist of PPAR gamma, on melanoma cells as a potential agent for repurposing in melanoma treatment. Methods: Expression of AGTR1 and PPAR gamma mRNA in melanoma patient tumor samples was examined in publicly available datasets and confirmed in melanoma cell lines by qRT-PCR. A panel of melanoma cell lines was tested in viability, apoptosis and metabolic assays in presence of telmisartan by flow cytometry and immunocytochemistry. A cytotoxic effect of combinations of telmisartan and targeted therapy vemurafenib was examined using the Chou-Talalay combination index method. Results: Both AGTR1 and PPAR gamma mRNA were expressed in melanoma patient tumor samples and decreased compared to the expression in the healthy skin. In vitro, we found that telmisartan decreased melanoma cell viability by inducing cell apoptosis. Increased glucose uptake, but not utilization, in the presence of telmisartan caused the fission of mitochondria and release of reactive oxygen species. Telmisartan altered the cell bioenergetics, thereby synergizing with vemurafenib in vitro, and even sensitized vemurafenib-resistant cells to the treatment. Conclusions: Given that the effective doses of telmisartan examined in our study can be administered to patients and that telmisartan is a widely used and safe antihypertensive drug, our findings provide the scientific rationale for testing its efficacy in treatment of melanoma progression.
PB  - Chinese Anti-Cancer Assoc, Tianjin
T2  - Cancer Biology & Medicine
T1  - Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics
EP  - +
IS  - 2
SP  - 247
VL  - 16
DO  - 10.20892/j.issn.2095-3941.2018.0375
ER  - 

@article{
author = "Grahovac, Jelena and Srdić-Rajić, Tatjana and Santibanez, Juan F. and Pavlović, Marijana and Cavić, Milena and Radulović, Siniša",
year = "2019",
abstract = "Objective: Despite recent advancements in targeted therapy and immunotherapies, prognosis for metastatic melanoma patients remains extremely poor. Development of resistance to previously effective treatments presents a serious challenge and new approaches for melanoma treatment are urgently needed. The objective of this study was to examine the effects of telmisartan, an AGTR1 inhibitor and a partial agonist of PPAR gamma, on melanoma cells as a potential agent for repurposing in melanoma treatment. Methods: Expression of AGTR1 and PPAR gamma mRNA in melanoma patient tumor samples was examined in publicly available datasets and confirmed in melanoma cell lines by qRT-PCR. A panel of melanoma cell lines was tested in viability, apoptosis and metabolic assays in presence of telmisartan by flow cytometry and immunocytochemistry. A cytotoxic effect of combinations of telmisartan and targeted therapy vemurafenib was examined using the Chou-Talalay combination index method. Results: Both AGTR1 and PPAR gamma mRNA were expressed in melanoma patient tumor samples and decreased compared to the expression in the healthy skin. In vitro, we found that telmisartan decreased melanoma cell viability by inducing cell apoptosis. Increased glucose uptake, but not utilization, in the presence of telmisartan caused the fission of mitochondria and release of reactive oxygen species. Telmisartan altered the cell bioenergetics, thereby synergizing with vemurafenib in vitro, and even sensitized vemurafenib-resistant cells to the treatment. Conclusions: Given that the effective doses of telmisartan examined in our study can be administered to patients and that telmisartan is a widely used and safe antihypertensive drug, our findings provide the scientific rationale for testing its efficacy in treatment of melanoma progression.",
publisher = "Chinese Anti-Cancer Assoc, Tianjin",
journal = "Cancer Biology & Medicine",
title = "Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics",
pages = "+-247",
number = "2",
volume = "16",
doi = "10.20892/j.issn.2095-3941.2018.0375"
}

Grahovac, J., Srdić-Rajić, T., Santibanez, J. F., Pavlović, M., Cavić, M.,& Radulović, S.. (2019). Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics. in Cancer Biology & Medicine
Chinese Anti-Cancer Assoc, Tianjin., 16(2), 247-+.
https://doi.org/10.20892/j.issn.2095-3941.2018.0375

Grahovac J, Srdić-Rajić T, Santibanez JF, Pavlović M, Cavić M, Radulović S. Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics. in Cancer Biology & Medicine. 2019;16(2):247-+.
doi:10.20892/j.issn.2095-3941.2018.0375 .

Grahovac, Jelena, Srdić-Rajić, Tatjana, Santibanez, Juan F., Pavlović, Marijana, Cavić, Milena, Radulović, Siniša, "Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics" in Cancer Biology & Medicine, 16, no. 2 (2019):247-+,
https://doi.org/10.20892/j.issn.2095-3941.2018.0375 . .

TY  - JOUR
AU  - Srdić-Rajić, Tatjana
AU  - Santibanez, Juan F.
AU  - Kanjer, Ksenija
AU  - Tišma-Miletić, Nevena
AU  - Cavić, Milena
AU  - Galun, Daniel
AU  - Jevrić, Marko
AU  - Kardum, Nevena Đ.
AU  - Konić-Ristić, Aleksandra
AU  - Zoranović, Tamara
PY  - 2018
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/859
PB  - Nature Publishing Group, London
T2  - Scientific Reports
T1  - Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells (vol 7, 3763, 2017)
VL  - 8
DO  - 10.1038/s41598-018-31450-1
ER  - 

@article{
author = "Srdić-Rajić, Tatjana and Santibanez, Juan F. and Kanjer, Ksenija and Tišma-Miletić, Nevena and Cavić, Milena and Galun, Daniel and Jevrić, Marko and Kardum, Nevena Đ. and Konić-Ristić, Aleksandra and Zoranović, Tamara",
year = "2018",
publisher = "Nature Publishing Group, London",
journal = "Scientific Reports",
title = "Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells (vol 7, 3763, 2017)",
volume = "8",
doi = "10.1038/s41598-018-31450-1"
}

Srdić-Rajić, T., Santibanez, J. F., Kanjer, K., Tišma-Miletić, N., Cavić, M., Galun, D., Jevrić, M., Kardum, N. Đ., Konić-Ristić, A.,& Zoranović, T.. (2018). Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells (vol 7, 3763, 2017). in Scientific Reports
Nature Publishing Group, London., 8.
https://doi.org/10.1038/s41598-018-31450-1

Srdić-Rajić T, Santibanez JF, Kanjer K, Tišma-Miletić N, Cavić M, Galun D, Jevrić M, Kardum NĐ, Konić-Ristić A, Zoranović T. Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells (vol 7, 3763, 2017). in Scientific Reports. 2018;8.
doi:10.1038/s41598-018-31450-1 .

Srdić-Rajić, Tatjana, Santibanez, Juan F., Kanjer, Ksenija, Tišma-Miletić, Nevena, Cavić, Milena, Galun, Daniel, Jevrić, Marko, Kardum, Nevena Đ., Konić-Ristić, Aleksandra, Zoranović, Tamara, "Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells (vol 7, 3763, 2017)" in Scientific Reports, 8 (2018),
https://doi.org/10.1038/s41598-018-31450-1 . .

TY  - JOUR
AU  - Srdić-Rajić, Tatjana
AU  - Santibanez, Juan F.
AU  - Kanjer, Ksenija
AU  - Tišma-Miletić, Nevena
AU  - Cavić, Milena
AU  - Galun, Daniel
AU  - Jevrić, Marko
AU  - Kardum, Nevena Đ.
AU  - Konić-Ristić, Aleksandra
AU  - Zoranović, Tamara
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/819
AB  - Chemotherapy in patients with inoperable or advanced breast cancer inevitably results in low-dose exposure of tumor-cell subset and senescence. Metabolically active senescent cells secrete multiple tumor promoting factors making their elimination a therapeutic priority. Viscum album is one of the most widely used alternative anti-cancer medicines facilitating chemotherapy tolerance of breast cancer patients. The aim of this study was to model and investigate how Viscum album extracts execute additive anti-tumor activity with low-dose Dox using ER + MCF7 breast cancer cells. We report that cotreatment of MCF7 with Viscum album and Dox abrogates G2/M cycle arrest replacing senescence with intrinsic apoptotic program. Mechanistically, this switch was associated with down-regulation of p21, p53/p73 as well as Erk1/2 and p38 activation. Our findings, therefore, identify a novel mechanistic axis of additive antitumor activity of Viscum album and low dose-Dox. In conclusion, ER + breast cancer patients may benefit from addition of Viscum album to low-dose Dox chemotherapy due to suppression of cancer cell senescence and induction of apoptosis.
PB  - Nature Publishing Group, London
T2  - Scientific Reports
T1  - Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells
SP  - 3763
VL  - 7
DO  - 10.1038/s41598-017-03898-0
ER  - 

@article{
author = "Srdić-Rajić, Tatjana and Santibanez, Juan F. and Kanjer, Ksenija and Tišma-Miletić, Nevena and Cavić, Milena and Galun, Daniel and Jevrić, Marko and Kardum, Nevena Đ. and Konić-Ristić, Aleksandra and Zoranović, Tamara",
year = "2017",
abstract = "Chemotherapy in patients with inoperable or advanced breast cancer inevitably results in low-dose exposure of tumor-cell subset and senescence. Metabolically active senescent cells secrete multiple tumor promoting factors making their elimination a therapeutic priority. Viscum album is one of the most widely used alternative anti-cancer medicines facilitating chemotherapy tolerance of breast cancer patients. The aim of this study was to model and investigate how Viscum album extracts execute additive anti-tumor activity with low-dose Dox using ER + MCF7 breast cancer cells. We report that cotreatment of MCF7 with Viscum album and Dox abrogates G2/M cycle arrest replacing senescence with intrinsic apoptotic program. Mechanistically, this switch was associated with down-regulation of p21, p53/p73 as well as Erk1/2 and p38 activation. Our findings, therefore, identify a novel mechanistic axis of additive antitumor activity of Viscum album and low dose-Dox. In conclusion, ER + breast cancer patients may benefit from addition of Viscum album to low-dose Dox chemotherapy due to suppression of cancer cell senescence and induction of apoptosis.",
publisher = "Nature Publishing Group, London",
journal = "Scientific Reports",
title = "Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells",
pages = "3763",
volume = "7",
doi = "10.1038/s41598-017-03898-0"
}

Srdić-Rajić, T., Santibanez, J. F., Kanjer, K., Tišma-Miletić, N., Cavić, M., Galun, D., Jevrić, M., Kardum, N. Đ., Konić-Ristić, A.,& Zoranović, T.. (2017). Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. in Scientific Reports
Nature Publishing Group, London., 7, 3763.
https://doi.org/10.1038/s41598-017-03898-0

Srdić-Rajić T, Santibanez JF, Kanjer K, Tišma-Miletić N, Cavić M, Galun D, Jevrić M, Kardum NĐ, Konić-Ristić A, Zoranović T. Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. in Scientific Reports. 2017;7:3763.
doi:10.1038/s41598-017-03898-0 .

Srdić-Rajić, Tatjana, Santibanez, Juan F., Kanjer, Ksenija, Tišma-Miletić, Nevena, Cavić, Milena, Galun, Daniel, Jevrić, Marko, Kardum, Nevena Đ., Konić-Ristić, Aleksandra, Zoranović, Tamara, "Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells" in Scientific Reports, 7 (2017):3763,
https://doi.org/10.1038/s41598-017-03898-0 . .

TY  - JOUR
AU  - Besu, Irina
AU  - Srdić-Rajić, Tatjana
AU  - Matić, Ivana Z.
AU  - Janković, Ljiljana
AU  - Besu, Valeri
AU  - Konić-Ristić, Aleksandra
AU  - Juranič, Zorica
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1245
AB  - Despite the numerous benefits of milk constituents for human health a considerable number of the general population follow a milk-restricted diet due to clinically confirmed or self-assessed adverse reactions to cow’s milk consumption. Recurrent aphthous ulcers (RAU) are currently one of the most common oral disorders, with a worldwide distribution and insufficiently defined etiology, which, among other factors, implies the immunological reaction to food proteins. The aim of this study was to determine the immune-reactivity to donkey’s milk proteins in patients with RAU and compare it to the reactivity towards the proteins from cow’s and goat’s milks, in a set of simultaneous experiments. Levels of serum IgA, IgG and IgE antibodies to the same quantity of the examined antigens were determined by enzyme-linked immunosorbent assay. The results indicate that patients with RAU with increased immunity to cow’s milk proteins could consider the use of donkey’s milk as the best protein source.
PB  - Taylor & Francis
T2  - Food and Agricultural Immunology
T1  - The absence of immunoreactivity to donkey’s milk in patients with recurrent aphthous ulcers and immunoreactivity to cow’s milk
EP  - 462
IS  - 3
SP  - 452
VL  - 28
DO  - 10.1080/09540105.2017.1293017
ER  - 

@article{
author = "Besu, Irina and Srdić-Rajić, Tatjana and Matić, Ivana Z. and Janković, Ljiljana and Besu, Valeri and Konić-Ristić, Aleksandra and Juranič, Zorica",
year = "2017",
abstract = "Despite the numerous benefits of milk constituents for human health a considerable number of the general population follow a milk-restricted diet due to clinically confirmed or self-assessed adverse reactions to cow’s milk consumption. Recurrent aphthous ulcers (RAU) are currently one of the most common oral disorders, with a worldwide distribution and insufficiently defined etiology, which, among other factors, implies the immunological reaction to food proteins. The aim of this study was to determine the immune-reactivity to donkey’s milk proteins in patients with RAU and compare it to the reactivity towards the proteins from cow’s and goat’s milks, in a set of simultaneous experiments. Levels of serum IgA, IgG and IgE antibodies to the same quantity of the examined antigens were determined by enzyme-linked immunosorbent assay. The results indicate that patients with RAU with increased immunity to cow’s milk proteins could consider the use of donkey’s milk as the best protein source.",
publisher = "Taylor & Francis",
journal = "Food and Agricultural Immunology",
title = "The absence of immunoreactivity to donkey’s milk in patients with recurrent aphthous ulcers and immunoreactivity to cow’s milk",
pages = "462-452",
number = "3",
volume = "28",
doi = "10.1080/09540105.2017.1293017"
}

Besu, I., Srdić-Rajić, T., Matić, I. Z., Janković, L., Besu, V., Konić-Ristić, A.,& Juranič, Z.. (2017). The absence of immunoreactivity to donkey’s milk in patients with recurrent aphthous ulcers and immunoreactivity to cow’s milk. in Food and Agricultural Immunology
Taylor & Francis., 28(3), 452-462.
https://doi.org/10.1080/09540105.2017.1293017

Besu I, Srdić-Rajić T, Matić IZ, Janković L, Besu V, Konić-Ristić A, Juranič Z. The absence of immunoreactivity to donkey’s milk in patients with recurrent aphthous ulcers and immunoreactivity to cow’s milk. in Food and Agricultural Immunology. 2017;28(3):452-462.
doi:10.1080/09540105.2017.1293017 .

Besu, Irina, Srdić-Rajić, Tatjana, Matić, Ivana Z., Janković, Ljiljana, Besu, Valeri, Konić-Ristić, Aleksandra, Juranič, Zorica, "The absence of immunoreactivity to donkey’s milk in patients with recurrent aphthous ulcers and immunoreactivity to cow’s milk" in Food and Agricultural Immunology, 28, no. 3 (2017):452-462,
https://doi.org/10.1080/09540105.2017.1293017 . .

TY  - JOUR
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Tišma-Miletić, Nevena
AU  - Kardum, Nevena Đ.
AU  - Galun, Daniel
AU  - Sikimić, Jelena
AU  - Glibetić, Marija
AU  - Milićević, Miroslav
PY  - 2015
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/618
AB  - BACKGROUND: Viscum album preparations are extensively used as complementary therapy in cancer and are shown to exert antitumor activities which involve the cytotoxic properties, induction of apoptosis, inhibition of angiogenesis and several other immunomodulatory mechanisms. AIM: The aim of this study was to investigate the eft fects of mistletoe extract on platelet as well as monocyte functions, as an important factors in immunomodulation of cancers metas tatic potencial and angiogenesis in tumors. METHODS: The effect of different concentrations of mistletoe extract on agonist-induced platelet activation markers and their aggregation with leukocytes was examined in the blood of healthy subjects ( n = 6 ) using flow cytometry. Effects on LPS -induced activation markers was det ermined in the blood of healthy subj ects as well as on THP- 1 cell line using an ELISA essays and flow cytometry. RESULTS: Mistletoe extract significantly inhibited agonist induced P selectin expression and platelet-monocytes aggregation. Additionally, mistletoe extract exerts anti-tumor effect through the stimulation of TNF-a production in LPS induced monocytes activation. CONCLUSION: Obtained data demonstrate that mistletoe extract was effective in modulating platelet and monocyte functions, as a part of pleiotropic anticancer effect.
AB  - UVOD: Preparati biljke Viscum album se intenzivno koriste kao komplementarna terapija u lecenju kancera. Mehanizmi antitumorskog delovanja, potvrđeni in vitro, ukljucuju citotoksicno delovanje, indukciju apoptoze, inhibiciju angiogeneze, imunomodulatorno delovanje. CILJ: Cilj ovog istraživanja je ispitivanje uticaja ekstrakta bele imele na funkciju trombocita i monocita kao važnih faktora u imunomodulaciji kancerskog procesa, metastatskom potencijalu i tumorskoj angiogenezi. METODE: Uticaj razlicitih koncentracija ekstrakta bele imele na markere agonistom indukovane aktivacije trombocita i njihove agregacije sa leukocitima ispitivan je u krvi zdravih ispitanika (n=6) primenom protocne citometrije. Uticaj na markere LPS indukovane aktivacije određivan je u krvi ispitanika i kulturi THP-1 celija korišceenjem ELISA eseja i protocne citometrije. REZULTATI: Ekstrakt imele znacajno inhibira ekspresiju P-selektina i trombocitno-monocitnu agregaciju. Pokazana stimulacija produkcije TNF-a u LPS-om aktiviranim monocitima dodatno doprinosi antitumorskom potencijalu. ZAKLJUČAK: Dobijeni rezultati potvrđuju potenci jal ekstrakta imele da modulira trombocitnu i monocitnu funkciju, kao deo pleotropnog antitumorskog delovanja.
PB  - Udruženje hirurga Jugoslavije, Beograd
T2  - Acta chirurgica iugoslavica
T1  - Effects of mistletoe extract on markers of platelet activation and aggregation
T1  - Efekti ekstrakta bele imele na markere aktivacije i agregacije trombocita
EP  - 13
IS  - 2
SP  - 5
VL  - 62
DO  - 10.2298/aci1502005S
ER  - 

@article{
author = "Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Tišma-Miletić, Nevena and Kardum, Nevena Đ. and Galun, Daniel and Sikimić, Jelena and Glibetić, Marija and Milićević, Miroslav",
year = "2015",
abstract = "BACKGROUND: Viscum album preparations are extensively used as complementary therapy in cancer and are shown to exert antitumor activities which involve the cytotoxic properties, induction of apoptosis, inhibition of angiogenesis and several other immunomodulatory mechanisms. AIM: The aim of this study was to investigate the eft fects of mistletoe extract on platelet as well as monocyte functions, as an important factors in immunomodulation of cancers metas tatic potencial and angiogenesis in tumors. METHODS: The effect of different concentrations of mistletoe extract on agonist-induced platelet activation markers and their aggregation with leukocytes was examined in the blood of healthy subjects ( n = 6 ) using flow cytometry. Effects on LPS -induced activation markers was det ermined in the blood of healthy subj ects as well as on THP- 1 cell line using an ELISA essays and flow cytometry. RESULTS: Mistletoe extract significantly inhibited agonist induced P selectin expression and platelet-monocytes aggregation. Additionally, mistletoe extract exerts anti-tumor effect through the stimulation of TNF-a production in LPS induced monocytes activation. CONCLUSION: Obtained data demonstrate that mistletoe extract was effective in modulating platelet and monocyte functions, as a part of pleiotropic anticancer effect., UVOD: Preparati biljke Viscum album se intenzivno koriste kao komplementarna terapija u lecenju kancera. Mehanizmi antitumorskog delovanja, potvrđeni in vitro, ukljucuju citotoksicno delovanje, indukciju apoptoze, inhibiciju angiogeneze, imunomodulatorno delovanje. CILJ: Cilj ovog istraživanja je ispitivanje uticaja ekstrakta bele imele na funkciju trombocita i monocita kao važnih faktora u imunomodulaciji kancerskog procesa, metastatskom potencijalu i tumorskoj angiogenezi. METODE: Uticaj razlicitih koncentracija ekstrakta bele imele na markere agonistom indukovane aktivacije trombocita i njihove agregacije sa leukocitima ispitivan je u krvi zdravih ispitanika (n=6) primenom protocne citometrije. Uticaj na markere LPS indukovane aktivacije određivan je u krvi ispitanika i kulturi THP-1 celija korišceenjem ELISA eseja i protocne citometrije. REZULTATI: Ekstrakt imele znacajno inhibira ekspresiju P-selektina i trombocitno-monocitnu agregaciju. Pokazana stimulacija produkcije TNF-a u LPS-om aktiviranim monocitima dodatno doprinosi antitumorskom potencijalu. ZAKLJUČAK: Dobijeni rezultati potvrđuju potenci jal ekstrakta imele da modulira trombocitnu i monocitnu funkciju, kao deo pleotropnog antitumorskog delovanja.",
publisher = "Udruženje hirurga Jugoslavije, Beograd",
journal = "Acta chirurgica iugoslavica",
title = "Effects of mistletoe extract on markers of platelet activation and aggregation, Efekti ekstrakta bele imele na markere aktivacije i agregacije trombocita",
pages = "13-5",
number = "2",
volume = "62",
doi = "10.2298/aci1502005S"
}

Srdić-Rajić, T., Konić-Ristić, A., Tišma-Miletić, N., Kardum, N. Đ., Galun, D., Sikimić, J., Glibetić, M.,& Milićević, M.. (2015). Effects of mistletoe extract on markers of platelet activation and aggregation. in Acta chirurgica iugoslavica
Udruženje hirurga Jugoslavije, Beograd., 62(2), 5-13.
https://doi.org/10.2298/aci1502005S

Srdić-Rajić T, Konić-Ristić A, Tišma-Miletić N, Kardum NĐ, Galun D, Sikimić J, Glibetić M, Milićević M. Effects of mistletoe extract on markers of platelet activation and aggregation. in Acta chirurgica iugoslavica. 2015;62(2):5-13.
doi:10.2298/aci1502005S .

Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Tišma-Miletić, Nevena, Kardum, Nevena Đ., Galun, Daniel, Sikimić, Jelena, Glibetić, Marija, Milićević, Miroslav, "Effects of mistletoe extract on markers of platelet activation and aggregation" in Acta chirurgica iugoslavica, 62, no. 2 (2015):5-13,
https://doi.org/10.2298/aci1502005S . .

TY  - JOUR
AU  - Konić-Ristić, Aleksandra
AU  - Savikin, Katarina
AU  - Zdunić, Gordana
AU  - Besu, Irina
AU  - Menković, Nebojša
AU  - Glibetić, Marija
AU  - Srdić-Rajić, Tatjana
PY  - 2015
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/660
AB  - The role of saliva in maintaining oral health and homeostasis is based on its physicochemical properties and biological activities of its components, including salivary immunoglobulin A (IgA). Both salivary rates and immunological status of saliva are found to be compromised in smokers. The aim of this study was to investigate the acute time-dependent effect of smoking and black currant consumption on the salivary flow rate (SFR) and salivary IgA secretion rate (sIgA SR) in healthy smokers. SFR, sIgA levels in saliva, and sIgA SRs were determined in healthy smokers (n=8) at eight times of assessment within three consecutive interventions: at the baseline; 5, 30, and 60 min after smoking; 5, 30, and 60 min after black currant consumption (100 g), followed by smoking; and 5 min after black currant consumption. Smoking induced a significant delayed effect on SFR measured 60 min after smoking (P=.03), while black currant consumption preceding smoking prevented that effect. Salivary IgA concentrations and sIgA flow rates were not acutely influenced by smoking. Black currant consumption preceding smoking induced a significant decrease in sIgA concentrations 5 min after the intervention compared with the baseline (P=.046), with a further increasing trend, statistically significant, 60 min after the intervention (P=.025). Although smoking cessation is the most important strategy in the prevention of chronic diseases, the obtained results suggest that the influence of black currant consumption on negative effects of tobacco smoke on salivary flow and immunological status of saliva could partly reduce the smoking-associated risk on oral health.
PB  - Mary Ann Liebert, Inc, New Rochelle
T2  - Journal of Medicinal Food
T1  - Acute Effects of Black Currant Consumption on Salivary Flow Rate and Secretion Rate of Salivary Immunoglobulin A in Healthy Smokers
EP  - 488
IS  - 4
SP  - 483
VL  - 18
DO  - 10.1089/jmf.2013.0149
ER  - 

@article{
author = "Konić-Ristić, Aleksandra and Savikin, Katarina and Zdunić, Gordana and Besu, Irina and Menković, Nebojša and Glibetić, Marija and Srdić-Rajić, Tatjana",
year = "2015",
abstract = "The role of saliva in maintaining oral health and homeostasis is based on its physicochemical properties and biological activities of its components, including salivary immunoglobulin A (IgA). Both salivary rates and immunological status of saliva are found to be compromised in smokers. The aim of this study was to investigate the acute time-dependent effect of smoking and black currant consumption on the salivary flow rate (SFR) and salivary IgA secretion rate (sIgA SR) in healthy smokers. SFR, sIgA levels in saliva, and sIgA SRs were determined in healthy smokers (n=8) at eight times of assessment within three consecutive interventions: at the baseline; 5, 30, and 60 min after smoking; 5, 30, and 60 min after black currant consumption (100 g), followed by smoking; and 5 min after black currant consumption. Smoking induced a significant delayed effect on SFR measured 60 min after smoking (P=.03), while black currant consumption preceding smoking prevented that effect. Salivary IgA concentrations and sIgA flow rates were not acutely influenced by smoking. Black currant consumption preceding smoking induced a significant decrease in sIgA concentrations 5 min after the intervention compared with the baseline (P=.046), with a further increasing trend, statistically significant, 60 min after the intervention (P=.025). Although smoking cessation is the most important strategy in the prevention of chronic diseases, the obtained results suggest that the influence of black currant consumption on negative effects of tobacco smoke on salivary flow and immunological status of saliva could partly reduce the smoking-associated risk on oral health.",
publisher = "Mary Ann Liebert, Inc, New Rochelle",
journal = "Journal of Medicinal Food",
title = "Acute Effects of Black Currant Consumption on Salivary Flow Rate and Secretion Rate of Salivary Immunoglobulin A in Healthy Smokers",
pages = "488-483",
number = "4",
volume = "18",
doi = "10.1089/jmf.2013.0149"
}

Konić-Ristić, A., Savikin, K., Zdunić, G., Besu, I., Menković, N., Glibetić, M.,& Srdić-Rajić, T.. (2015). Acute Effects of Black Currant Consumption on Salivary Flow Rate and Secretion Rate of Salivary Immunoglobulin A in Healthy Smokers. in Journal of Medicinal Food
Mary Ann Liebert, Inc, New Rochelle., 18(4), 483-488.
https://doi.org/10.1089/jmf.2013.0149

Konić-Ristić A, Savikin K, Zdunić G, Besu I, Menković N, Glibetić M, Srdić-Rajić T. Acute Effects of Black Currant Consumption on Salivary Flow Rate and Secretion Rate of Salivary Immunoglobulin A in Healthy Smokers. in Journal of Medicinal Food. 2015;18(4):483-488.
doi:10.1089/jmf.2013.0149 .

Konić-Ristić, Aleksandra, Savikin, Katarina, Zdunić, Gordana, Besu, Irina, Menković, Nebojša, Glibetić, Marija, Srdić-Rajić, Tatjana, "Acute Effects of Black Currant Consumption on Salivary Flow Rate and Secretion Rate of Salivary Immunoglobulin A in Healthy Smokers" in Journal of Medicinal Food, 18, no. 4 (2015):483-488,
https://doi.org/10.1089/jmf.2013.0149 . .

TY  - JOUR
AU  - Zec, Manja M.
AU  - Srdić-Rajić, Tatjana
AU  - Krivokuca, Ana
AU  - Janković, Radmila
AU  - Todorović, Tamara
AU  - Anđelković, Katarina
AU  - Radulović, Siniša
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/561
AB  - The synthesis and chemical characterization of the novel 2,6-diacetylpyridine-bis(selenosemicarbazone) metal complexes of Zn(II), Cd(II) and Ni(II) were published previously. Here we report first evidence on anti-proliferative activity of the complexes and molecular patterns that underlie it. The complexes and the corresponding ligand are shown to be cytotoxic on the panel of nine, malignant and non-malignant cell lines, with the exception of Ni(II) complex that did not achieve IC50 value on any of the cell lines tested. Further experiments on the selected cell lines including A 549, MRC-5, EA.hy 926 and HeLa, have shown that the complexes posses unambiguous property of inducing necrosis in the cells treated for 6 hours, with the ligand and Zn(II) complex being the most active on all cell lines. On the contrary, only small portion of early apoptotic events was detected, under the same experimental condition. This was in complete concordance with the results obtained from Western blot analysis of the treated cells that showed no or slight increase of the protein amounts of two crucial apoptotic mediators: Cytochrome C and Caspase III. We propose the model, under which tested complexes induce necroptosis in treated cells, a recently described type of cell death with necrotic morphological features and acting via caspase independent pathway, and without elevated amounts of intracellular ROS. Endothelial EA.hy 926 cells have proven to be extremely sensitive on the necrosis-inducing effect of the complexes, which could indicate potential anti-angiogenic effect of the novel complexes that is to be investigated.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Medicinal Chemistry
T1  - Novel Selenosemicarbazone Metal Complexes Exert Anti-tumor Effect via Alternative, Caspase-independent Necroptotic Cell Death
EP  - 771
IS  - 8
SP  - 759
VL  - 10
DO  - 10.2174/1573406410666140327122009
ER  - 

@article{
author = "Zec, Manja M. and Srdić-Rajić, Tatjana and Krivokuca, Ana and Janković, Radmila and Todorović, Tamara and Anđelković, Katarina and Radulović, Siniša",
year = "2014",
abstract = "The synthesis and chemical characterization of the novel 2,6-diacetylpyridine-bis(selenosemicarbazone) metal complexes of Zn(II), Cd(II) and Ni(II) were published previously. Here we report first evidence on anti-proliferative activity of the complexes and molecular patterns that underlie it. The complexes and the corresponding ligand are shown to be cytotoxic on the panel of nine, malignant and non-malignant cell lines, with the exception of Ni(II) complex that did not achieve IC50 value on any of the cell lines tested. Further experiments on the selected cell lines including A 549, MRC-5, EA.hy 926 and HeLa, have shown that the complexes posses unambiguous property of inducing necrosis in the cells treated for 6 hours, with the ligand and Zn(II) complex being the most active on all cell lines. On the contrary, only small portion of early apoptotic events was detected, under the same experimental condition. This was in complete concordance with the results obtained from Western blot analysis of the treated cells that showed no or slight increase of the protein amounts of two crucial apoptotic mediators: Cytochrome C and Caspase III. We propose the model, under which tested complexes induce necroptosis in treated cells, a recently described type of cell death with necrotic morphological features and acting via caspase independent pathway, and without elevated amounts of intracellular ROS. Endothelial EA.hy 926 cells have proven to be extremely sensitive on the necrosis-inducing effect of the complexes, which could indicate potential anti-angiogenic effect of the novel complexes that is to be investigated.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Medicinal Chemistry",
title = "Novel Selenosemicarbazone Metal Complexes Exert Anti-tumor Effect via Alternative, Caspase-independent Necroptotic Cell Death",
pages = "771-759",
number = "8",
volume = "10",
doi = "10.2174/1573406410666140327122009"
}

Zec, M. M., Srdić-Rajić, T., Krivokuca, A., Janković, R., Todorović, T., Anđelković, K.,& Radulović, S.. (2014). Novel Selenosemicarbazone Metal Complexes Exert Anti-tumor Effect via Alternative, Caspase-independent Necroptotic Cell Death. in Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 10(8), 759-771.
https://doi.org/10.2174/1573406410666140327122009

Zec MM, Srdić-Rajić T, Krivokuca A, Janković R, Todorović T, Anđelković K, Radulović S. Novel Selenosemicarbazone Metal Complexes Exert Anti-tumor Effect via Alternative, Caspase-independent Necroptotic Cell Death. in Medicinal Chemistry. 2014;10(8):759-771.
doi:10.2174/1573406410666140327122009 .

Zec, Manja M., Srdić-Rajić, Tatjana, Krivokuca, Ana, Janković, Radmila, Todorović, Tamara, Anđelković, Katarina, Radulović, Siniša, "Novel Selenosemicarbazone Metal Complexes Exert Anti-tumor Effect via Alternative, Caspase-independent Necroptotic Cell Death" in Medicinal Chemistry, 10, no. 8 (2014):759-771,
https://doi.org/10.2174/1573406410666140327122009 . .

TY  - JOUR
AU  - Konić-Ristić, Aleksandra
AU  - Srdić-Rajić, Tatjana
AU  - Kardum, Nevena Đ.
AU  - Glibetić, Marija
PY  - 2013
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/469
AB  - The beneficial effects of black chokeberry fruits and juices in health promotion and prevention of chronic diseases shown in both epidemiological and dietary intervention studies are often connected with their antioxidant activity. The aim of this study was to investigate the total phenolics and anthocyanins content, chemical antioxidant activity (DPPH-assay), antioxidant protection in erythrocytes and anti-platelet activity in vitro of three different chokeberry products: commercial and fresh pure chokeberry juice and a crude lyophilized water-ethanol extract of chokeberry fruits, as part of their pre-clinical evaluation. The obtained results indicated differences in chemical composition and antioxidant activity of the investigated products. Cellular effects, including both in vitro anti-platelet and antioxidant effects, were not directly correlated with the chemical antioxidant activity and the results obtained in vitro for antiplatelet effects were only partially consistent with the results obtained in vivo, in a pilot intervention trial. In conclusion, chemical analyses and in vitro experiments on foods and their bioactive substances are a valuable pre-screening tool for the evaluation of their biological activity. However, extrapolation of the obtained results to the in vivo settings is often limited and influenced by the bioavailability and metabolism of native dietary compounds or interactions with differrent molecules within the human body.
PB  - Srpsko hemijsko društvo, Beograd
T2  - Journal of the Serbian Chemical Society
T1  - Biological activity of Aronia melanocarpa antioxidants pre-screening in an intervention study design
EP  - 443
IS  - 3
SP  - 429
VL  - 78
DO  - 10.2298/JSC121213020K
ER  - 

@article{
author = "Konić-Ristić, Aleksandra and Srdić-Rajić, Tatjana and Kardum, Nevena Đ. and Glibetić, Marija",
year = "2013",
abstract = "The beneficial effects of black chokeberry fruits and juices in health promotion and prevention of chronic diseases shown in both epidemiological and dietary intervention studies are often connected with their antioxidant activity. The aim of this study was to investigate the total phenolics and anthocyanins content, chemical antioxidant activity (DPPH-assay), antioxidant protection in erythrocytes and anti-platelet activity in vitro of three different chokeberry products: commercial and fresh pure chokeberry juice and a crude lyophilized water-ethanol extract of chokeberry fruits, as part of their pre-clinical evaluation. The obtained results indicated differences in chemical composition and antioxidant activity of the investigated products. Cellular effects, including both in vitro anti-platelet and antioxidant effects, were not directly correlated with the chemical antioxidant activity and the results obtained in vitro for antiplatelet effects were only partially consistent with the results obtained in vivo, in a pilot intervention trial. In conclusion, chemical analyses and in vitro experiments on foods and their bioactive substances are a valuable pre-screening tool for the evaluation of their biological activity. However, extrapolation of the obtained results to the in vivo settings is often limited and influenced by the bioavailability and metabolism of native dietary compounds or interactions with differrent molecules within the human body.",
publisher = "Srpsko hemijsko društvo, Beograd",
journal = "Journal of the Serbian Chemical Society",
title = "Biological activity of Aronia melanocarpa antioxidants pre-screening in an intervention study design",
pages = "443-429",
number = "3",
volume = "78",
doi = "10.2298/JSC121213020K"
}

Konić-Ristić, A., Srdić-Rajić, T., Kardum, N. Đ.,& Glibetić, M.. (2013). Biological activity of Aronia melanocarpa antioxidants pre-screening in an intervention study design. in Journal of the Serbian Chemical Society
Srpsko hemijsko društvo, Beograd., 78(3), 429-443.
https://doi.org/10.2298/JSC121213020K

Konić-Ristić A, Srdić-Rajić T, Kardum NĐ, Glibetić M. Biological activity of Aronia melanocarpa antioxidants pre-screening in an intervention study design. in Journal of the Serbian Chemical Society. 2013;78(3):429-443.
doi:10.2298/JSC121213020K .

Konić-Ristić, Aleksandra, Srdić-Rajić, Tatjana, Kardum, Nevena Đ., Glibetić, Marija, "Biological activity of Aronia melanocarpa antioxidants pre-screening in an intervention study design" in Journal of the Serbian Chemical Society, 78, no. 3 (2013):429-443,
https://doi.org/10.2298/JSC121213020K . .

TY  - JOUR
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Vucić, M.
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Ilić, Vesna
AU  - Milić, Nataša
AU  - Bila, Jelena
AU  - Suvajdžić-Vuković, Nada
AU  - Virijević, Marijana
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2013
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/510
AB  - The study included 48 untreated patients with monoclonal gammopathies (MG). Paraprotein was isolated from the serum of 10 patients with decreased platelet aggregation. Platelet aggregation was measured before and after the addition of the isolated paraprotein to platelet-rich plasma (PRP) from 10 healthy donors, in vitro. Expression of platelet von Willebrand factor (vWF) receptor glycoprotein (GP)Ib and platelet collagen receptor GPVI was determined by flow cytometry in the PRP of healthy donors before and after the addition of isolated paraprotein using the monoclonal antibodies, CD42b (for GPIb) and CD36 (for GPVI). Flowcytometry showed that expression of CD42b and CD36 positive cells was reduced after the addition of isolated paraprotein to PRP from healthy donors (p  lt  0.001). These investigations demonstrated that paraprotein causes platelet dysfunction in patients with MG due to specific binding to the platelet vWF receptor GPIb and platelet collagen receptor GPVI. Copyright (c) 2013 S. Karger AG, Basel
PB  - Karger, Basel
T2  - Acta Haematologica
T1  - Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies
EP  - 107
IS  - 2
SP  - 101
VL  - 130
DO  - 10.1159/000345418
ER  - 

@article{
author = "Đunić, I. and Elezović, Ivo and Vucić, M. and Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Ilić, Vesna and Milić, Nataša and Bila, Jelena and Suvajdžić-Vuković, Nada and Virijević, Marijana and Antić, Darko and Vidović, Ana and Tomin, Dragica",
year = "2013",
abstract = "The study included 48 untreated patients with monoclonal gammopathies (MG). Paraprotein was isolated from the serum of 10 patients with decreased platelet aggregation. Platelet aggregation was measured before and after the addition of the isolated paraprotein to platelet-rich plasma (PRP) from 10 healthy donors, in vitro. Expression of platelet von Willebrand factor (vWF) receptor glycoprotein (GP)Ib and platelet collagen receptor GPVI was determined by flow cytometry in the PRP of healthy donors before and after the addition of isolated paraprotein using the monoclonal antibodies, CD42b (for GPIb) and CD36 (for GPVI). Flowcytometry showed that expression of CD42b and CD36 positive cells was reduced after the addition of isolated paraprotein to PRP from healthy donors (p  lt  0.001). These investigations demonstrated that paraprotein causes platelet dysfunction in patients with MG due to specific binding to the platelet vWF receptor GPIb and platelet collagen receptor GPVI. Copyright (c) 2013 S. Karger AG, Basel",
publisher = "Karger, Basel",
journal = "Acta Haematologica",
title = "Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies",
pages = "107-101",
number = "2",
volume = "130",
doi = "10.1159/000345418"
}

Đunić, I., Elezović, I., Vucić, M., Srdić-Rajić, T., Konić-Ristić, A., Ilić, V., Milić, N., Bila, J., Suvajdžić-Vuković, N., Virijević, M., Antić, D., Vidović, A.,& Tomin, D.. (2013). Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies. in Acta Haematologica
Karger, Basel., 130(2), 101-107.
https://doi.org/10.1159/000345418

Đunić I, Elezović I, Vucić M, Srdić-Rajić T, Konić-Ristić A, Ilić V, Milić N, Bila J, Suvajdžić-Vuković N, Virijević M, Antić D, Vidović A, Tomin D. Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies. in Acta Haematologica. 2013;130(2):101-107.
doi:10.1159/000345418 .

Đunić, I., Elezović, Ivo, Vucić, M., Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Ilić, Vesna, Milić, Nataša, Bila, Jelena, Suvajdžić-Vuković, Nada, Virijević, Marijana, Antić, Darko, Vidović, Ana, Tomin, Dragica, "Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies" in Acta Haematologica, 130, no. 2 (2013):101-107,
https://doi.org/10.1159/000345418 . .

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Vucić, M.
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Ilić, Vesna
AU  - Milić, Nataša
AU  - Bila, J.
AU  - Suvajdžić-Vuković, Nada
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2012
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/416
PB  - Wiley-Blackwell, Hoboken
C3  - Haemophilia
T1  - Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies
EP  - 195
SP  - 195
VL  - 18
UR  - https://hdl.handle.net/21.15107/rcub_rimi_416
ER  - 

@conference{
author = "Đunić, I. and Elezović, Ivo and Vucić, M. and Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Ilić, Vesna and Milić, Nataša and Bila, J. and Suvajdžić-Vuković, Nada and Antić, Darko and Vidović, Ana and Tomin, Dragica",
year = "2012",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Haemophilia",
title = "Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies",
pages = "195-195",
volume = "18",
url = "https://hdl.handle.net/21.15107/rcub_rimi_416"
}

Đunić, I., Elezović, I., Vucić, M., Srdić-Rajić, T., Konić-Ristić, A., Ilić, V., Milić, N., Bila, J., Suvajdžić-Vuković, N., Antić, D., Vidović, A.,& Tomin, D.. (2012). Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies. in Haemophilia
Wiley-Blackwell, Hoboken., 18, 195-195.
https://hdl.handle.net/21.15107/rcub_rimi_416

Đunić I, Elezović I, Vucić M, Srdić-Rajić T, Konić-Ristić A, Ilić V, Milić N, Bila J, Suvajdžić-Vuković N, Antić D, Vidović A, Tomin D. Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies. in Haemophilia. 2012;18:195-195.
https://hdl.handle.net/21.15107/rcub_rimi_416 .

Đunić, I., Elezović, Ivo, Vucić, M., Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Ilić, Vesna, Milić, Nataša, Bila, J., Suvajdžić-Vuković, Nada, Antić, Darko, Vidović, Ana, Tomin, Dragica, "Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies" in Haemophilia, 18 (2012):195-195,
https://hdl.handle.net/21.15107/rcub_rimi_416 .

TY  - CONF
AU  - Đunić, I.
AU  - Elezović, Ivo
AU  - Vucić, M.
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Ilić, Vesna
AU  - Milić, Nataša
AU  - Bila, J.
AU  - Suvajdžić-Vuković, Nada
AU  - Virijević, Marijana
AU  - Antić, Darko
AU  - Vidović, Ana
AU  - Tomin, Dragica
PY  - 2012
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/452
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies
EP  - 197
SP  - 196
VL  - 97
UR  - https://hdl.handle.net/21.15107/rcub_rimi_452
ER  - 

@conference{
author = "Đunić, I. and Elezović, Ivo and Vucić, M. and Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Ilić, Vesna and Milić, Nataša and Bila, J. and Suvajdžić-Vuković, Nada and Virijević, Marijana and Antić, Darko and Vidović, Ana and Tomin, Dragica",
year = "2012",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies",
pages = "197-196",
volume = "97",
url = "https://hdl.handle.net/21.15107/rcub_rimi_452"
}

Đunić, I., Elezović, I., Vucić, M., Srdić-Rajić, T., Konić-Ristić, A., Ilić, V., Milić, N., Bila, J., Suvajdžić-Vuković, N., Virijević, M., Antić, D., Vidović, A.,& Tomin, D.. (2012). Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies. in Haematologica
Ferrata Storti Foundation, Pavia., 97, 196-197.
https://hdl.handle.net/21.15107/rcub_rimi_452

Đunić I, Elezović I, Vucić M, Srdić-Rajić T, Konić-Ristić A, Ilić V, Milić N, Bila J, Suvajdžić-Vuković N, Virijević M, Antić D, Vidović A, Tomin D. Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies. in Haematologica. 2012;97:196-197.
https://hdl.handle.net/21.15107/rcub_rimi_452 .

Đunić, I., Elezović, Ivo, Vucić, M., Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Ilić, Vesna, Milić, Nataša, Bila, J., Suvajdžić-Vuković, Nada, Virijević, Marijana, Antić, Darko, Vidović, Ana, Tomin, Dragica, "Specific binding of paraprotein to platelet receptors as a cause of platelet disfunction in monoclonal gammopathies" in Haematologica, 97 (2012):196-197,
https://hdl.handle.net/21.15107/rcub_rimi_452 .

TY  - CONF
AU  - Grozdanić, N.
AU  - Stanojković, T. P.
AU  - Kljajić, Z.
AU  - Etahiri, S.
AU  - Assobhei, O.
AU  - Konić-Ristić, Aleksandra
AU  - Srdić-Rajić, Tatjana
AU  - Kardum, Nevena Đ.
AU  - Backović, S.
PY  - 2012
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/398
PB  - Elsevier Sci Ltd, Oxford
C3  - European Journal of Cancer
T1  - In Vitro Evaluation of Antioxidant and Antitumoral Activities of Marine Algae Gelidium Sesquipedale and Fucus Spiralis
EP  - S26
SP  - S26
VL  - 48
DO  - 10.1016/S0959-8049(12)70809-2
ER  - 

@conference{
author = "Grozdanić, N. and Stanojković, T. P. and Kljajić, Z. and Etahiri, S. and Assobhei, O. and Konić-Ristić, Aleksandra and Srdić-Rajić, Tatjana and Kardum, Nevena Đ. and Backović, S.",
year = "2012",
publisher = "Elsevier Sci Ltd, Oxford",
journal = "European Journal of Cancer",
title = "In Vitro Evaluation of Antioxidant and Antitumoral Activities of Marine Algae Gelidium Sesquipedale and Fucus Spiralis",
pages = "S26-S26",
volume = "48",
doi = "10.1016/S0959-8049(12)70809-2"
}

Grozdanić, N., Stanojković, T. P., Kljajić, Z., Etahiri, S., Assobhei, O., Konić-Ristić, A., Srdić-Rajić, T., Kardum, N. Đ.,& Backović, S.. (2012). In Vitro Evaluation of Antioxidant and Antitumoral Activities of Marine Algae Gelidium Sesquipedale and Fucus Spiralis. in European Journal of Cancer
Elsevier Sci Ltd, Oxford., 48, S26-S26.
https://doi.org/10.1016/S0959-8049(12)70809-2

Grozdanić N, Stanojković TP, Kljajić Z, Etahiri S, Assobhei O, Konić-Ristić A, Srdić-Rajić T, Kardum NĐ, Backović S. In Vitro Evaluation of Antioxidant and Antitumoral Activities of Marine Algae Gelidium Sesquipedale and Fucus Spiralis. in European Journal of Cancer. 2012;48:S26-S26.
doi:10.1016/S0959-8049(12)70809-2 .

Grozdanić, N., Stanojković, T. P., Kljajić, Z., Etahiri, S., Assobhei, O., Konić-Ristić, Aleksandra, Srdić-Rajić, Tatjana, Kardum, Nevena Đ., Backović, S., "In Vitro Evaluation of Antioxidant and Antitumoral Activities of Marine Algae Gelidium Sesquipedale and Fucus Spiralis" in European Journal of Cancer, 48 (2012):S26-S26,
https://doi.org/10.1016/S0959-8049(12)70809-2 . .

TY  - JOUR
AU  - Zec, Manja M.
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Todorović, Tamara
AU  - Anđelković, Katarina
AU  - Filipovic-Ljesković, Ivana
AU  - Radulović, Siniša
PY  - 2012
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/391
AB  - Our previous studies showed that zinc (II), cadmium (II) and nickel (II) complexes with 2-formylpyridine selenose-micarbazone induce apoptosis in cancer cells via activation of mitochondrial pathway. Herein, we reported their antimetastatic properties. Nickel (II), and zinc (II) complexes exhibited the strongest inhibitory potential towards MMP-2/9, while all investigated compounds significantly decreased proteolytic activity of MMP-2/9 in human breast cancer MDA-MB-361 cells. As shown by in vitro transmembrane assays, nickel (II) complex was the most effective in inhibiting invasion of MDA-MB-361 cells, while the cadmium (II) complex was the most active in inhibiting HeLa cells invasion. In malignant cells, the complexes inhibited intracellular accumulation of reactive oxygen species, known for its pro-angiogenic properties via VEGF signaling, but no reduction in total cellular amount of VEGF was found. Furthermore, tubulogenesis test showed anti-angiogenic effect of the complexes in treated endothelial cells. Data indicate multiple mechanisms of the complexes' anti-angiogenic properties. In addition, they could modulate metastatic phenotype of tumor cells. Nickel (II) complex with 2-formylpyridine selenosemicarbazone revealed to be the most potent.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Anti-Cancer Agents in Medicinal Chemistry
T1  - Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones
EP  - 1080
IS  - 9
SP  - 1071
VL  - 12
DO  - 10.2174/187152012803529682
ER  - 

@article{
author = "Zec, Manja M. and Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Todorović, Tamara and Anđelković, Katarina and Filipovic-Ljesković, Ivana and Radulović, Siniša",
year = "2012",
abstract = "Our previous studies showed that zinc (II), cadmium (II) and nickel (II) complexes with 2-formylpyridine selenose-micarbazone induce apoptosis in cancer cells via activation of mitochondrial pathway. Herein, we reported their antimetastatic properties. Nickel (II), and zinc (II) complexes exhibited the strongest inhibitory potential towards MMP-2/9, while all investigated compounds significantly decreased proteolytic activity of MMP-2/9 in human breast cancer MDA-MB-361 cells. As shown by in vitro transmembrane assays, nickel (II) complex was the most effective in inhibiting invasion of MDA-MB-361 cells, while the cadmium (II) complex was the most active in inhibiting HeLa cells invasion. In malignant cells, the complexes inhibited intracellular accumulation of reactive oxygen species, known for its pro-angiogenic properties via VEGF signaling, but no reduction in total cellular amount of VEGF was found. Furthermore, tubulogenesis test showed anti-angiogenic effect of the complexes in treated endothelial cells. Data indicate multiple mechanisms of the complexes' anti-angiogenic properties. In addition, they could modulate metastatic phenotype of tumor cells. Nickel (II) complex with 2-formylpyridine selenosemicarbazone revealed to be the most potent.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
title = "Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones",
pages = "1080-1071",
number = "9",
volume = "12",
doi = "10.2174/187152012803529682"
}

Zec, M. M., Srdić-Rajić, T., Konić-Ristić, A., Todorović, T., Anđelković, K., Filipovic-Ljesković, I.,& Radulović, S.. (2012). Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones. in Anti-Cancer Agents in Medicinal Chemistry
Bentham Science Publ Ltd, Sharjah., 12(9), 1071-1080.
https://doi.org/10.2174/187152012803529682

Zec MM, Srdić-Rajić T, Konić-Ristić A, Todorović T, Anđelković K, Filipovic-Ljesković I, Radulović S. Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones. in Anti-Cancer Agents in Medicinal Chemistry. 2012;12(9):1071-1080.
doi:10.2174/187152012803529682 .

Zec, Manja M., Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Todorović, Tamara, Anđelković, Katarina, Filipovic-Ljesković, Ivana, Radulović, Siniša, "Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones" in Anti-Cancer Agents in Medicinal Chemistry, 12, no. 9 (2012):1071-1080,
https://doi.org/10.2174/187152012803529682 . .

TY  - CONF
AU  - Srdić-Rajić, Tatjana
AU  - Konić-Ristić, Aleksandra
AU  - Arsić, Aleksandra
AU  - Zec, Manja M.
AU  - Kardum, Nevena Đ.
AU  - Stojanović, F.
AU  - Glibetić, Marija
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/360
PB  - Karger, Basel
C3  - Annals of Nutrition & Metabolism
T1  - Effect of aronia melanocarpa juice intake on antioxidative status and platelet function - Ex Vivo Study
EP  - 339
SP  - 339
VL  - 58
UR  - https://hdl.handle.net/21.15107/rcub_rimi_360
ER  - 

@conference{
author = "Srdić-Rajić, Tatjana and Konić-Ristić, Aleksandra and Arsić, Aleksandra and Zec, Manja M. and Kardum, Nevena Đ. and Stojanović, F. and Glibetić, Marija",
year = "2011",
publisher = "Karger, Basel",
journal = "Annals of Nutrition & Metabolism",
title = "Effect of aronia melanocarpa juice intake on antioxidative status and platelet function - Ex Vivo Study",
pages = "339-339",
volume = "58",
url = "https://hdl.handle.net/21.15107/rcub_rimi_360"
}

Srdić-Rajić, T., Konić-Ristić, A., Arsić, A., Zec, M. M., Kardum, N. Đ., Stojanović, F.,& Glibetić, M.. (2011). Effect of aronia melanocarpa juice intake on antioxidative status and platelet function - Ex Vivo Study. in Annals of Nutrition & Metabolism
Karger, Basel., 58, 339-339.
https://hdl.handle.net/21.15107/rcub_rimi_360

Srdić-Rajić T, Konić-Ristić A, Arsić A, Zec MM, Kardum NĐ, Stojanović F, Glibetić M. Effect of aronia melanocarpa juice intake on antioxidative status and platelet function - Ex Vivo Study. in Annals of Nutrition & Metabolism. 2011;58:339-339.
https://hdl.handle.net/21.15107/rcub_rimi_360 .

Srdić-Rajić, Tatjana, Konić-Ristić, Aleksandra, Arsić, Aleksandra, Zec, Manja M., Kardum, Nevena Đ., Stojanović, F., Glibetić, Marija, "Effect of aronia melanocarpa juice intake on antioxidative status and platelet function - Ex Vivo Study" in Annals of Nutrition & Metabolism, 58 (2011):339-339,
https://hdl.handle.net/21.15107/rcub_rimi_360 .

TY  - CONF
AU  - Petrović-Oggiano, Gordana P.
AU  - Konić-Ristić, Aleksandra
AU  - Srdić-Rajić, Tatjana
AU  - Stojanović, F.
AU  - Glibetić, Marija
AU  - Juranić, Z.
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/368
PB  - Karger, Basel
C3  - Annals of Nutrition & Metabolism
T1  - Immunereactivity to gliadin and milk proteins in patients with metabolic syndrome
EP  - 41
SP  - 41
VL  - 58
UR  - https://hdl.handle.net/21.15107/rcub_rimi_368
ER  - 

@conference{
author = "Petrović-Oggiano, Gordana P. and Konić-Ristić, Aleksandra and Srdić-Rajić, Tatjana and Stojanović, F. and Glibetić, Marija and Juranić, Z.",
year = "2011",
publisher = "Karger, Basel",
journal = "Annals of Nutrition & Metabolism",
title = "Immunereactivity to gliadin and milk proteins in patients with metabolic syndrome",
pages = "41-41",
volume = "58",
url = "https://hdl.handle.net/21.15107/rcub_rimi_368"
}

Petrović-Oggiano, G. P., Konić-Ristić, A., Srdić-Rajić, T., Stojanović, F., Glibetić, M.,& Juranić, Z.. (2011). Immunereactivity to gliadin and milk proteins in patients with metabolic syndrome. in Annals of Nutrition & Metabolism
Karger, Basel., 58, 41-41.
https://hdl.handle.net/21.15107/rcub_rimi_368

Petrović-Oggiano GP, Konić-Ristić A, Srdić-Rajić T, Stojanović F, Glibetić M, Juranić Z. Immunereactivity to gliadin and milk proteins in patients with metabolic syndrome. in Annals of Nutrition & Metabolism. 2011;58:41-41.
https://hdl.handle.net/21.15107/rcub_rimi_368 .

Petrović-Oggiano, Gordana P., Konić-Ristić, Aleksandra, Srdić-Rajić, Tatjana, Stojanović, F., Glibetić, Marija, Juranić, Z., "Immunereactivity to gliadin and milk proteins in patients with metabolic syndrome" in Annals of Nutrition & Metabolism, 58 (2011):41-41,
https://hdl.handle.net/21.15107/rcub_rimi_368 .

TY  - CONF
AU  - Konić-Ristić, Aleksandra
AU  - Stanojković, T.
AU  - Srdić-Rajić, Tatjana
AU  - Zdunić, Gordana
AU  - Savikin, Katarina
AU  - Glibetić, Marija
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/374
PB  - Karger, Basel
C3  - Annals of Nutrition & Metabolism
T1  - Anti-proliferative and cell-cycle effects of chokeberry and pomegranate juices on colon cancer cells in vitro
EP  - 365
SP  - 364
VL  - 58
UR  - https://hdl.handle.net/21.15107/rcub_rimi_374
ER  - 

@conference{
author = "Konić-Ristić, Aleksandra and Stanojković, T. and Srdić-Rajić, Tatjana and Zdunić, Gordana and Savikin, Katarina and Glibetić, Marija",
year = "2011",
publisher = "Karger, Basel",
journal = "Annals of Nutrition & Metabolism",
title = "Anti-proliferative and cell-cycle effects of chokeberry and pomegranate juices on colon cancer cells in vitro",
pages = "365-364",
volume = "58",
url = "https://hdl.handle.net/21.15107/rcub_rimi_374"
}

Konić-Ristić, A., Stanojković, T., Srdić-Rajić, T., Zdunić, G., Savikin, K.,& Glibetić, M.. (2011). Anti-proliferative and cell-cycle effects of chokeberry and pomegranate juices on colon cancer cells in vitro. in Annals of Nutrition & Metabolism
Karger, Basel., 58, 364-365.
https://hdl.handle.net/21.15107/rcub_rimi_374

Konić-Ristić A, Stanojković T, Srdić-Rajić T, Zdunić G, Savikin K, Glibetić M. Anti-proliferative and cell-cycle effects of chokeberry and pomegranate juices on colon cancer cells in vitro. in Annals of Nutrition & Metabolism. 2011;58:364-365.
https://hdl.handle.net/21.15107/rcub_rimi_374 .

Konić-Ristić, Aleksandra, Stanojković, T., Srdić-Rajić, Tatjana, Zdunić, Gordana, Savikin, Katarina, Glibetić, Marija, "Anti-proliferative and cell-cycle effects of chokeberry and pomegranate juices on colon cancer cells in vitro" in Annals of Nutrition & Metabolism, 58 (2011):364-365,
https://hdl.handle.net/21.15107/rcub_rimi_374 .

TY  - JOUR
AU  - Eshkourfu, Rabia
AU  - Cobeljić, Bzidar
AU  - Vujcić, Miroslava
AU  - Turel, Iztok
AU  - Pevec, Andrej
AU  - Sepcić, Kristina
AU  - Zec, Manja M.
AU  - Radulović, Siniša
AU  - Srdić-Rajić, Tatjana
AU  - Mitić, Dragana
AU  - Anđelković, Katarina
AU  - Sladić, Dušan
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/327
AB  - A novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide, N',N'(2)-bis[(1E)-1-(2-pyridyl)ethylidene]propanedihydrazide was synthesized and characterized by elemental analysis, spectroscopy (NMR and infrared), and X-ray crystal analysis. The complex showed a moderate activity towards Artemia salina. The highest cytotoxic potential of the complex was observed on the epithelial breast cancer (MDA-361) cell line. The investigated complex induced apoptosis, the early apoptotic cells comprising 28.18%, compared to 5.64% of control cells in the same phase. The interaction of the complex with calf thymus DNA (CT-DNA) was monitored by blue shift and hyperchromism in the UV-vis spectra. The observed intrinsic binding constant (K-b = 4.2 x 10(5) M-1) together with structural analysis of the complex indicate the groove binding.
PB  - Elsevier Science Inc, New York
T2  - Journal of Inorganic Biochemistry
T1  - Synthesis, characterization, cytotoxic activity and DNA binding properties of the novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide
EP  - 1203
IS  - 9
SP  - 1196
VL  - 105
DO  - 10.1016/j.jinorgbio.2011.05.024
ER  - 

@article{
author = "Eshkourfu, Rabia and Cobeljić, Bzidar and Vujcić, Miroslava and Turel, Iztok and Pevec, Andrej and Sepcić, Kristina and Zec, Manja M. and Radulović, Siniša and Srdić-Rajić, Tatjana and Mitić, Dragana and Anđelković, Katarina and Sladić, Dušan",
year = "2011",
abstract = "A novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide, N',N'(2)-bis[(1E)-1-(2-pyridyl)ethylidene]propanedihydrazide was synthesized and characterized by elemental analysis, spectroscopy (NMR and infrared), and X-ray crystal analysis. The complex showed a moderate activity towards Artemia salina. The highest cytotoxic potential of the complex was observed on the epithelial breast cancer (MDA-361) cell line. The investigated complex induced apoptosis, the early apoptotic cells comprising 28.18%, compared to 5.64% of control cells in the same phase. The interaction of the complex with calf thymus DNA (CT-DNA) was monitored by blue shift and hyperchromism in the UV-vis spectra. The observed intrinsic binding constant (K-b = 4.2 x 10(5) M-1) together with structural analysis of the complex indicate the groove binding.",
publisher = "Elsevier Science Inc, New York",
journal = "Journal of Inorganic Biochemistry",
title = "Synthesis, characterization, cytotoxic activity and DNA binding properties of the novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide",
pages = "1203-1196",
number = "9",
volume = "105",
doi = "10.1016/j.jinorgbio.2011.05.024"
}

Eshkourfu, R., Cobeljić, B., Vujcić, M., Turel, I., Pevec, A., Sepcić, K., Zec, M. M., Radulović, S., Srdić-Rajić, T., Mitić, D., Anđelković, K.,& Sladić, D.. (2011). Synthesis, characterization, cytotoxic activity and DNA binding properties of the novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide. in Journal of Inorganic Biochemistry
Elsevier Science Inc, New York., 105(9), 1196-1203.
https://doi.org/10.1016/j.jinorgbio.2011.05.024

Eshkourfu R, Cobeljić B, Vujcić M, Turel I, Pevec A, Sepcić K, Zec MM, Radulović S, Srdić-Rajić T, Mitić D, Anđelković K, Sladić D. Synthesis, characterization, cytotoxic activity and DNA binding properties of the novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide. in Journal of Inorganic Biochemistry. 2011;105(9):1196-1203.
doi:10.1016/j.jinorgbio.2011.05.024 .

Eshkourfu, Rabia, Cobeljić, Bzidar, Vujcić, Miroslava, Turel, Iztok, Pevec, Andrej, Sepcić, Kristina, Zec, Manja M., Radulović, Siniša, Srdić-Rajić, Tatjana, Mitić, Dragana, Anđelković, Katarina, Sladić, Dušan, "Synthesis, characterization, cytotoxic activity and DNA binding properties of the novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide" in Journal of Inorganic Biochemistry, 105, no. 9 (2011):1196-1203,
https://doi.org/10.1016/j.jinorgbio.2011.05.024 . .

TY  - JOUR
AU  - Srdić-Rajić, Tatjana
AU  - Zec, Manja M.
AU  - Todorović, Tamara
AU  - Anđelković, Katarina
AU  - Radulović, Siniša
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/334
AB  - We previously published the synthesis, characterization and cytotoxic effect of the novel Zn(II), Ni(II), and Cd(II) complexes with 2-formylpyridine selenosemicarbazone. Here we further investigate the mechanism of their antiproliferative activity against several cancer and vascular endothelial cell lines and compared it to the activity of the ligand itself, corresponding salts and, as a referent compound, cisplatin. Investigated complexes induced apoptosis in a time- and dose-dependent manner as well as changes in a cell cycle distribution. Caspase-3 activation in HeLa cells, MDA-MB-361 and vascular endothelial cells EA.hy 926 cells by ligand alone, as well as Zn(II), Ni(II), and Cd(II) complexes was preceded by the activation of the p53 tumor-suppressor gene family protein p73. In addition to activation of p73, these compounds also trigger cytochrome C release by upregulation of Bax expression. The release of cytochrome C has been linked to loss of mitochondrial membrane potential. However, our data indicated that the increased phosphorylation of ERK could be also one of the mechanism involved in the Zn(II), and Cd(II) complexes- induction of apoptosis. Selenosemicarbazone complexes with Cd(II) and Ni(II), possess dual ability to induce apoptosis as well as necrosis, and might present an added advantage for inducing cell death in a diverse array of malignant cells. Taken together, our findings could indicate potential role of these complexes as activator of cross-talk between different signaling pathways that leads to cell death, and thus making the complex intriguing field for further scientific, and maybe clinical investigations.
PB  - Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux
T2  - European Journal of Medicinal Chemistry
T1  - Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway
EP  - 3747
IS  - 9
SP  - 3734
VL  - 46
DO  - 10.1016/j.ejmech.2011.05.039
ER  - 

@article{
author = "Srdić-Rajić, Tatjana and Zec, Manja M. and Todorović, Tamara and Anđelković, Katarina and Radulović, Siniša",
year = "2011",
abstract = "We previously published the synthesis, characterization and cytotoxic effect of the novel Zn(II), Ni(II), and Cd(II) complexes with 2-formylpyridine selenosemicarbazone. Here we further investigate the mechanism of their antiproliferative activity against several cancer and vascular endothelial cell lines and compared it to the activity of the ligand itself, corresponding salts and, as a referent compound, cisplatin. Investigated complexes induced apoptosis in a time- and dose-dependent manner as well as changes in a cell cycle distribution. Caspase-3 activation in HeLa cells, MDA-MB-361 and vascular endothelial cells EA.hy 926 cells by ligand alone, as well as Zn(II), Ni(II), and Cd(II) complexes was preceded by the activation of the p53 tumor-suppressor gene family protein p73. In addition to activation of p73, these compounds also trigger cytochrome C release by upregulation of Bax expression. The release of cytochrome C has been linked to loss of mitochondrial membrane potential. However, our data indicated that the increased phosphorylation of ERK could be also one of the mechanism involved in the Zn(II), and Cd(II) complexes- induction of apoptosis. Selenosemicarbazone complexes with Cd(II) and Ni(II), possess dual ability to induce apoptosis as well as necrosis, and might present an added advantage for inducing cell death in a diverse array of malignant cells. Taken together, our findings could indicate potential role of these complexes as activator of cross-talk between different signaling pathways that leads to cell death, and thus making the complex intriguing field for further scientific, and maybe clinical investigations.",
publisher = "Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux",
journal = "European Journal of Medicinal Chemistry",
title = "Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway",
pages = "3747-3734",
number = "9",
volume = "46",
doi = "10.1016/j.ejmech.2011.05.039"
}

Srdić-Rajić, T., Zec, M. M., Todorović, T., Anđelković, K.,& Radulović, S.. (2011). Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway. in European Journal of Medicinal Chemistry
Elsevier France-Editions Scientifiques Medicales Elsevier, Issy-Les-Moulineaux., 46(9), 3734-3747.
https://doi.org/10.1016/j.ejmech.2011.05.039

Srdić-Rajić T, Zec MM, Todorović T, Anđelković K, Radulović S. Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway. in European Journal of Medicinal Chemistry. 2011;46(9):3734-3747.
doi:10.1016/j.ejmech.2011.05.039 .

Srdić-Rajić, Tatjana, Zec, Manja M., Todorović, Tamara, Anđelković, Katarina, Radulović, Siniša, "Non-substituted N-heteroaromatic selenosemicarbazone metal complexes induce apoptosis in cancer cells via activation of mitochondrial pathway" in European Journal of Medicinal Chemistry, 46, no. 9 (2011):3734-3747,
https://doi.org/10.1016/j.ejmech.2011.05.039 . .

TY  - JOUR
AU  - Bjelogrlić, Snežana
AU  - Todorović, Tamara
AU  - Bacchi, Alessia
AU  - Zec, Manja M.
AU  - Sladić, Dušan
AU  - Srdić-Rajić, Tatjana
AU  - Radanović, Dušanka
AU  - Radulović, Siniša
AU  - Pelizzi, Giancarlo
AU  - Anđelković, Katarina
PY  - 2010
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/286
AB  - Two novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide were synthesized. The structure of Cd(II) complex was determined by X-ray crystallography. The ligand is coordinated in a neutral form via pyridine and azomethine nitrogen atoms and the selenium donor. The cadmium ion completes its five-coordination by two chloride ligands, forming a square-pyramidal geometry. The structure of Zn(II) complex was established by analysis of spectroscopic data, which indicated coordination of the ligand as a bidentate via the selenium and the azomethine nitrogen atoms. The cytotoxic activity of the newly synthesized complexes, as well as if five structurally related complexes and the ligand evaluated against eight tumor cell lines. The new Cd(II) complex showed the highest activity similar to cisplatin with IC50 less than 10 mu M for all cell lines. Cell cycle distribution and apoptosis study showed that Cd(II) complex and cisplatin might have some similarity in anticancer activity, which was not the case for cisplatin and other studied complexes. Effects of the complexes on matrix metalloproteinases (MMPs) MMP-9 and MMP-2 was also studied. Cd(II) and Zn(II) complexes and cisplatin increased MMP-2 activity in supernatants of tested cells. while Ni(II) complex with the same ligand decreased the activity, implying a possible activity in preventing tumor invasion and metastasis processes.
PB  - Elsevier Science Inc, New York
T2  - Journal of Inorganic Biochemistry
T1  - Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes
EP  - 682
IS  - 6
SP  - 673
VL  - 104
DO  - 10.1016/j.jinorgbio.2010.02.009
ER  - 

@article{
author = "Bjelogrlić, Snežana and Todorović, Tamara and Bacchi, Alessia and Zec, Manja M. and Sladić, Dušan and Srdić-Rajić, Tatjana and Radanović, Dušanka and Radulović, Siniša and Pelizzi, Giancarlo and Anđelković, Katarina",
year = "2010",
abstract = "Two novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide were synthesized. The structure of Cd(II) complex was determined by X-ray crystallography. The ligand is coordinated in a neutral form via pyridine and azomethine nitrogen atoms and the selenium donor. The cadmium ion completes its five-coordination by two chloride ligands, forming a square-pyramidal geometry. The structure of Zn(II) complex was established by analysis of spectroscopic data, which indicated coordination of the ligand as a bidentate via the selenium and the azomethine nitrogen atoms. The cytotoxic activity of the newly synthesized complexes, as well as if five structurally related complexes and the ligand evaluated against eight tumor cell lines. The new Cd(II) complex showed the highest activity similar to cisplatin with IC50 less than 10 mu M for all cell lines. Cell cycle distribution and apoptosis study showed that Cd(II) complex and cisplatin might have some similarity in anticancer activity, which was not the case for cisplatin and other studied complexes. Effects of the complexes on matrix metalloproteinases (MMPs) MMP-9 and MMP-2 was also studied. Cd(II) and Zn(II) complexes and cisplatin increased MMP-2 activity in supernatants of tested cells. while Ni(II) complex with the same ligand decreased the activity, implying a possible activity in preventing tumor invasion and metastasis processes.",
publisher = "Elsevier Science Inc, New York",
journal = "Journal of Inorganic Biochemistry",
title = "Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes",
pages = "682-673",
number = "6",
volume = "104",
doi = "10.1016/j.jinorgbio.2010.02.009"
}

Bjelogrlić, S., Todorović, T., Bacchi, A., Zec, M. M., Sladić, D., Srdić-Rajić, T., Radanović, D., Radulović, S., Pelizzi, G.,& Anđelković, K.. (2010). Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes. in Journal of Inorganic Biochemistry
Elsevier Science Inc, New York., 104(6), 673-682.
https://doi.org/10.1016/j.jinorgbio.2010.02.009

Bjelogrlić S, Todorović T, Bacchi A, Zec MM, Sladić D, Srdić-Rajić T, Radanović D, Radulović S, Pelizzi G, Anđelković K. Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes. in Journal of Inorganic Biochemistry. 2010;104(6):673-682.
doi:10.1016/j.jinorgbio.2010.02.009 .

Bjelogrlić, Snežana, Todorović, Tamara, Bacchi, Alessia, Zec, Manja M., Sladić, Dušan, Srdić-Rajić, Tatjana, Radanović, Dušanka, Radulović, Siniša, Pelizzi, Giancarlo, Anđelković, Katarina, "Synthesis, structure and characterization of novel Cd(II) and Zn(II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide Antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes" in Journal of Inorganic Biochemistry, 104, no. 6 (2010):673-682,
https://doi.org/10.1016/j.jinorgbio.2010.02.009 . .